Combination of ascorbate/epigallocatechin-3-gallate/gemcitabine synergistically induces cell cycle deregulation and apoptosis in mesothelioma cells

Simona Martinotti, Elia Ranzato, Monica Parodi, Massimo Vitale, Bruno Burlando

Research output: Contribution to journalArticle

Abstract

Malignant mesothelioma (MMe) is a poor-prognosis tumor in need of innovative therapies. In a previous in vivo study, we showed synergistic anti-MMe properties of the ascorbate/epigallocatechin-3-gallate/gemcitabine combination. We have now focused on the mechanism of action, showing the induction of apoptosis and cell cycle arrest through measurements of caspase 3, intracellular Ca2+, annexin V, and DNA content. StellArray™ PCR technology and Western immunoblotting revealed DAPK2-dependent apoptosis, upregulation of cell cycle promoters, downregulation of cell cycle checkpoints and repression of NFκB expression. The complex of data indicates that the mixture is synergistic in inducing cell cycle deregulation and non-inflammatory apoptosis, suggesting its possible use in MMe treatment.

Original languageEnglish
Pages (from-to)35-41
Number of pages7
JournalToxicology and Applied Pharmacology
Volume274
Issue number1
DOIs
Publication statusPublished - Jan 1 2014

Keywords

  • Cell cycle
  • Combined therapy
  • DAPK2
  • PCR array
  • REN mesothelioma cells

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Fingerprint Dive into the research topics of 'Combination of ascorbate/epigallocatechin-3-gallate/gemcitabine synergistically induces cell cycle deregulation and apoptosis in mesothelioma cells'. Together they form a unique fingerprint.

  • Cite this